MedTrace Logo

Anemia-Related Outcomes in Patients With CKD Treated With Dapagliflozin

NCT06813222 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2025-02-06

No results posted yet for this study

Summary

Anemia-Related Outcomes in Patients with CKD Treated with Dapagliflozin

This study aims to identify factors that predict anemia improvement in chronic kidney disease (CKD) patients using Dapagliflozin, an SGLT2 inhibitor.

Key questions:

* What factors influence how well Dapagliflozin improves anemia in CKD patients?
* Are there specific characteristics that predict better responses to Dapagliflozin treatment?

The investigators will review medical records of CKD patients who started taking Dapagliflozin. The investigators will compare those with low hemoglobin levels (anemia) to those without anemia.

The investigators will analyze:

Changes in hemoglobin levels Other factors related to anemia (e.g., iron levels, TIBC, ferritin) Patient characteristics (e.g., age, sex, CKD stage)

This study will help us understand which CKD patients are most likely to benefit from Dapagliflozin for anemia.

Conditions

Interventions

DRUG

Dapagliflozin (DAPA)

Dapagliflozin 10 mg

Sponsors & Collaborators

  • Damanhour University

    lead OTHER

Principal Investigators

  • Amira Kassem, BPharm, MS, PhD · Faculty of Pharmacy, Damanhour University, Egypt

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2025-03-01
Completion
2025-03-01
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06813222 on ClinicalTrials.gov